Feb 23, 2018ATXA Therapeutics receives EMA Orphan Drug Designation for NTP42 for the treatment of Pulmonary ArteDUBLIN, IRELAND – February 23, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...
Feb 2, 2018ATXA Therapeutics to Present at the 2018 Biotech and Money / Medtech and Money World Congress ShowcaDUBLIN, IRELAND – February 2, 2018 – ATXA Therapeutics Limited, an early-stage Irish biopharmaceutical company focused on clinical...